Researchers reported a number of important findings in pancreatic cancer treatment at the 2019 Annual Meeting of the American Society of Clinical Oncology:

PARP inhibitor delays disease progression in metastatic pancreatic cancer with inherited BRCA mutation

The results of POLO, a large phase III trial, found that the PARP inhibitor olaparib is effective at delaying disease progression in people with metastatic pancreatic cancer who have an inherited BRCA mutation.

What Patients Need to Know

PARP is a type of enzyme that helps repair DNA. In cancer treatment, PARP inhibitors are used to prevent cancer cells from repairing their damaged DNA. This can cause the cancer cells to die, especially those with the cancer-predisposition genes BRCA1 or BRCA2.

Addition of nab-paclitaxel to gemcitabine in adjuvant treatment evaluated

The global phase III APACT trial evaluated the chemotherapy combination of nab-paclitaxel plus gemcitabine versus gemcitabine alone in the adjuvant (post-surgery) treatment of pancreatic cancer.

What Patients Need to Know

An independent review of the trial results found that adding nab-paclitaxel to adjuvant gemcitabine did not significantly prolong disease-free survival.

Rivaroxaban reduces VTE in patients with pancreatic cancer

According to the results from a subgroup analysis of the CASSINI study, rivaroxaban substantially reduces venous thromboembolism (VTE) in people with pancreatic cancer, without increasing the incidence of major bleeding events.

What Patients Need to Know

Rivaroxaban is an anticoagulant used to treat deep vein thrombosis (DVT) and pulmonary embolism. The findings indicate the potential benefit of including rivaroxaban as part of a systemic treatment regimen for pancreatic cancer.